1 cartridge (3 ml) contains 300 IU. human isophane insulin.
Action:
The preparation contains an intermediate-acting human insulin, obtained by recombinant bacterial DNAE. coli. Insulin reduces serum Glucose by inhibiting hepatic glucose production (glucogenolysis and gluconeogenesis) and increases glucose transport to muscle and fat cells as well as increasing intracellular glucose consumption. Insulin inhibits lipolysis and stimulates the synthesis of fatty acids, reduces the formation of ketone bodies. The hormone stimulates the synthesis of proteins and inhibits their breakdown in the muscles and other tissues of the body. After subcutaneous administration, the onset of action occurs within approx. 1.5 h, maximum effect - after 4-12 h, the total duration of action is 24 h.
Contraindications:
Hypersensitivity to the components of the preparation. Hypoglycemia.
Precautions:
In patients with renal and (or) hepatic insufficiency, the need for insulin may be reduced. Caution use in patients with pituitary and adrenal insufficiency due to the increased risk of hypoglycaemia. Patients who plan to travel to a different time zone, meal times and insulin injections may change. Insulin requirements can be changed during illness or stressful situations. A change to another type of insulin or insulin of another origin should be under strict medical supervision and may require a change in dosage.
Pregnancy and lactation:
The preparation can be used during pregnancy. The insulin requirement usually decreases in the first trimester and gradually increases during the second and third trimesters of pregnancy, decreases at the moment of delivery, after delivery it quickly returns to pre-pregnancy value. There is no restriction on the use of the product during breastfeeding, however dose adjustment may be necessary.
Side effects:
Most often: hypoglycaemia. Common: local allergic reaction. The site of insulin administration may include: redness, swelling, itching, pain, hematoma. Uncommon: lipodystrophy, hypertrophy (sometimes in places distant from the site of insulin administration). Very rare: anaphylactic reactions.
Dosage:
Individually, according to the need for insulin. In children, normoglycemia should be sought, the most appropriate is functional insulin therapy. In patients with renal and (or) hepatic insufficiency, the insulin dose should be reduced accordingly. In elderly patients (over 70 years of age), normoglycaemia should not be sought; An algorithm of 2 insulin injections is recommended, maintaining a blood glucose below the kidney threshold is often sufficient. Patients with obesity may require increased insulin doses. The product is administered subcutaneously in the abdominal region, buttocks, thigh or upper arm. It is necessary to change the injection site in the area of one anatomical region, so that the same place is used no more frequently than once a month.
(C)
